Targeting DNA repair pathways for cancer treatment: what’s new?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kaelin WG Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 1(10), 99 (2009).
  MedlineGoogle Scholar
• 2 Bapat A, Fishel ML, Kelley MR. Going ape as an approach to cancer therapeutics. Antioxid. Redox Signal. 11(3), 651–668 (2009).
  Medline CASGoogle Scholar
• 3 Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer Res. 16(18), 4527–4531 (2010).
  Medline CASGoogle Scholar
• 4 Luo M, He H, Kelley MR, Georgiadis MM. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid. Redox Signal. 12(11), 1247–1269 (2010).
  Medline CASGoogle Scholar
• 5 Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst.) 6(8), 1079–1099 (2007).
  Medline CASGoogle Scholar
• 6 Kelley MR, Georgiadis MM, Fishel ML. DNA repair and redox signaling. In: The Tumor Microenvironment. Bagley R (Ed.). Springer, NY, USA, 133–168 (2010).
  Google Scholar
• 7 De Lartigue J. New life for PARP inhibitors: emerging agents leave mark at ASCO.www.onclive.com/publications/oncology-live/2013/august-2013/new-life-for-parp-inhibitors-emerging-agents-leave-mark-at-asco/4 • Documents the recent trials and tribulations in the use of PARP inhibitors with future directions.
  Google Scholar
• 8 Bryant HE, Schultz N, Thomas HD et al. Specific tumor-killing of BRCA-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434(14), 913–917 (2005).
  Medline CASGoogle Scholar
• 9 Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann. Oncol. 22(2), 268–279 (2011).
  Medline CASGoogle Scholar
• 10 Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol. Med. 17(7–8), 854–862 (2011).
  Medline CASGoogle Scholar
• 11 ClinicalTrials.gov. https://clinicaltrials.gov 
  Google Scholar
• 12 O’Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364(3), 205–214 (2011).
  MedlineGoogle Scholar
• 13 De Lartigue J. The PARP inhibitors: down but not out (2012). www.onclive.com/publications/oncology-live/2012/july-2012/the-parp-inhibitors-down-but-not-out/2
  Google Scholar
• 14 Guha M. PARP inhibitors stumble in breast cancer. Nat. Biotechnol. 29(5), 373–374 (2011).
  Medline CASGoogle Scholar
• 15 Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front. Oncol. 3(290), 1–11 (2013).
  MedlineGoogle Scholar
• 16 Papao G, Casale E, Montagnoli A, Circla A. PARP inhibitors in cancer therapy: an update. Expert Opin. Ther. Pat. 23(4), 503–514 (2013).
  MedlineGoogle Scholar
• 17 Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10(4), 293–301 (2010).
  Medline CASGoogle Scholar
• 18 AZD2461 (2013). www.selleckchem.com/products/azd2461.html
  Google Scholar
• 19 Newswire G. BioMarin provides updated Phase 1/2 data on BMN 673 in breast cancer at the european cancer congress 2013. 1, 1 (2013). www.marketwatch.com/story/biomarin-provides-updated-phase-12-data-on-bmn-673-in-breast-cancer-at-the-european-cancer-congress-2013-2013-09-29
  Google Scholar
• 20 Murai J, Huang SY, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72(21), 5588–5599 (2012).
  Medline CASGoogle Scholar
• 21 McNeely S, Beckmann R, Lin AB. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol. Ther. 142(1), 1–10, (2013).
  MedlineGoogle Scholar
• 22 Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O⁽⁶⁾-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 4, e876 (2013).
  Medline CASGoogle Scholar
• 23 Golding SE, Rosenberg E, Adams BR et al. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 11(6), 1167–1173 (2012).
  Medline CASGoogle Scholar
• 24 Maxmen A. Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms. J. Natl Cancer Inst. 102(15), 1110–1111 (2010).
  MedlineGoogle Scholar
• 25 Golding SE, Rosenberg E, Valerie N et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 8(10), 2894–2902 (2009).
  Medline CASGoogle Scholar
• 26 Kaina B, Muhlhausen U, Piee-Staffa A et al. Inhibition of O⁶-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J. Pharmacol. Exp. Ther. 311(2), 585–593 (2004).
  Medline CASGoogle Scholar
• 27 Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4(4), 296–307 (2004).
  Medline CASGoogle Scholar
• 28 Kelley MR, Fishel ML. DNA Repair and Cancer Therapeutics. In: Principles of Molecular Diagnostics and Personalized Cancer Medicine. Tan D, Lynch HT (Eds). Lippincott Williams & Wilkins, PA, USA, 566–579 (2013).
  Google Scholar
• 29 Fortini P, Dogliotti E. Base damage and single-strand break repair: mechanisms and functional significance of short- and long-patch repair subpathways. DNA Repair 6(4), 398–409 (2007).
  Medline CASGoogle Scholar
• 30 Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell. Mol. Life Sci. 66(6), 981–993 (2009).
  Medline CASGoogle Scholar
• 31 Fishel ML, Vascotto C, Kelley MR. DNA base excision repair therapeutics: summary of targets with a focus on APE1. In: DNA Repair and Cancer: From Bench to Clinic. Madhusudan S, Wilson DM (Eds). CRC Press, FL, USA, 233–287 (2013).•• Strong review of the DNA base excision repair (BER) pathway and implications for cancer therapies.
  Google Scholar
• 32 Scalia M, Satriano C, Greca R, Stella AM, Rizzarelli E, Spina-Purrello V. PARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells. Neurochem. Res. 38(1), 50–58 (2013).
  Medline CASGoogle Scholar
• 33 Srinivasan A, Gold B. Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. Future Med. Chem. 4(9), 1093–1111 (2012).
  Medline CASGoogle Scholar
• 34 Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr. Mol. Pharmacol. 5(1), 36–53 (2012).
  Medline CASGoogle Scholar
• 35 Jaiswal AS, Banerjee S, Aneja R, Sarkar FH, Ostrov DA, Narayan S. DNA polymerase beta as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS ONE 6(2), e16691 (2011).
  Medline CASGoogle Scholar
• 36 Rai G, Vyjayanti VN, Dorjsuren D et al. Small molecule inhibitors of the human apurinic/apyrimidinic endonuclease 1 (APE1). National Center for Biotechnology Information, MD, USA, 27 (2010).
  Google Scholar
• 37 Bapat A, Glass LS, Luo M et al. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J. Pharmacol. Exp. Ther. 334(3), 988–998 (2010).
  Medline CASGoogle Scholar
• 38 Abbotts R, Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 36(5), 425–435 (2010).
  Medline CASGoogle Scholar
• 39 Gao Z, Maloney DJ, Dedkova LM, Hecht SM. Inhibitors of DNA polymerase beta: activity and mechanism. Bioorg. Med. Chem. 16(8), 4331–4340 (2008).
  Medline CASGoogle Scholar
• 40 Hegde ML, Hazra TK, Mitra S. Functions of disordered regions in mammalian early base excision repair proteins. Cell. Mol. Life Sci. 67(21), 3573–3587 (2010).
  Medline CASGoogle Scholar
• 41 Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J. Cell. Phys. 219(1), 209–218 (2009).
  Medline CASGoogle Scholar
• 42 Kelley MR, Fishel ML. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med. Chem. 8(4), 417–425 (2008).
  Medline CASGoogle Scholar
• 43 Tell G, Wilson DM 3rd. Targeting DNA repair proteins for cancer treatment. Cell. Mol. Life Sci. 67(21), 3569–3572 (2010).
  Medline CASGoogle Scholar
• 44 Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox Signal. 11(3), 601–620 (2009).• Strong review on the multifunctions of a critical DNA repair protein.
  Medline CASGoogle Scholar
• 45 Fishel ML, Jiang Y, Rajeshkumar NV et al. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol. Cancer Ther. 10(9), 1698–1708 (2011).
  Medline CASGoogle Scholar
• 46 Cardoso AA, Jiang Y, Luo M et al. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1–STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. PLoS ONE 7(10), e47462 (2012).• Novel report of a critical transcription factor under redox control by a multifunctional DNA repair and redox signaling protein.
  Medline CASGoogle Scholar
• 47 Methoxyamine clinical trials (2013). www.clinicaltrials.gov/ct2/results?term=methoxyamine+&Search=Search
  Google Scholar
• 48 Reed AM, Fishel ML, Kelley MR. Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol. 5(5), 713–726 (2009).
  CASGoogle Scholar
• 49 Li M, Wilson DM 3rd. Human apurinic/apyrimidinic endonuclease 1. Antioxid Redox Signal. 20(4), 678–707 (2013).
  MedlineGoogle Scholar
• 50 Sultana R, McNeill DR, Abbotts R et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 131(10), 2433–2444 (2012).
  Medline CASGoogle Scholar
• 51 Wilson DM 3rd, Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell. Mol. Life Sci. 67(21), 3621–3631 (2010).
  Medline CASGoogle Scholar
• 52 ApeX Therapeutics Research (2013). http://apextherapeutics.com/research.
  Google Scholar
• 53 Tsutakawa SE, Classen S, Chapados BR et al. Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily. Cell 145(2), 198–211 (2011).
  Medline CASGoogle Scholar
• 54 Van Pel DM, Barrett IJ, Shimizu Y et al. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. 9(1), e1003254 (2013).
  Medline CASGoogle Scholar
• 55 Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin. Cancer Res. 16(21), 5107–5113 (2010).
  Medline CASGoogle Scholar
• 56 Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 18(1), 85–98 (2008).
  Medline CASGoogle Scholar
• 57 Li YH, Wang X, Pan Y, Lee DH, Chowdhury D, Kimmelman AC. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS ONE 7(6), e39588 (2012).
  Medline CASGoogle Scholar
• 58 Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency (MESH). http://clinicaltrials.gov/ct2/show/NCT00952016
  Google Scholar
• 59 Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 71(5), 1836–1848 (2011).• Strong presentation of development of new therapeutic agents for a mismatch DNA repair target protein.
  Medline CASGoogle Scholar
• 60 Dianov G. Repair pathways for processing of 8-oxoguanine in DNA by mammalian cell extracts. J. Biol. Chem. 273(50), 33811–33816 (1998).
  Medline CASGoogle Scholar
• 61 Kinsella TJ. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin. Cancer Res. 15(6), 1853–1859 (2009).
  Medline CASGoogle Scholar
• 62 Neher TM, Bodenmiller D, Fitch RW, Jalal SI, Turchi JJ. Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin. Mol. Cancer Ther. 10(10), 1796–1806 (2011).
  Medline CASGoogle Scholar
• 63 Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair, from understanding mechanisms to influencing biology. Cell Res. 18(1), 64–72 (2008).
  Medline CASGoogle Scholar
• 64 Barakat KH, Tuszynski JA. Nucleotide excision repair inhibitors: still a long way to go. In: New Research Directions in DNA Repair. Chen C (Ed.). InTech, AZ, USA, 559–576 (2013).
  Google Scholar
• 65 Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, Tuszynski JA. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS ONE 7(12), e51329 (2012).
  Medline CASGoogle Scholar
• 66 UCN-01 clinical trials (2013). www.clinicaltrials.gov/ct2/results?term=UCN-01&pg=1.
  Google Scholar
• 67 Barret JM, Cadou M, Hill BT. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochem. Pharmacol. 63(2), 251–258 (2002).
  Medline CASGoogle Scholar
• 68 D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 9(8), 2157–2163 (2010).
  MedlineGoogle Scholar
• 69 Trabectedin clinical trials (2013). www.clinicaltrials.gov/ct2/results?term=trabectedin+&Search=Search.
  Google Scholar
• 70 Mcneil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 40(20), 9990–10004 (2012).
  Medline CASGoogle Scholar
• 71 Usanova S, Piee-Staffa A, Sied U et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol. Cancer 9, 248 (2010).
  MedlineGoogle Scholar
• 72 Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res. 40(13), 5795–5818 (2012).
  Medline CASGoogle Scholar
• 73 Neal JA, Dang V, Douglas P, Wold MS, Lees-Miller SP, Meek K. Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation. Mol. Cell Biol. 31(8), 1719–1733 (2011).
  Medline CASGoogle Scholar
• 74 Chernikova SB, Game JC, Brown JM. Inhibiting homologous recombination for cancer therapy. Cancer Biol. Ther. 13(2), 61–68 (2012).
  Medline CASGoogle Scholar
• 75 Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31(6), 955–960 (2010).
  Medline CASGoogle Scholar
• 76 Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8(3), 193–204 (2008).
  Medline CASGoogle Scholar
• 77 Yan H, Toczylowski T, McCane J, Chen C, Liao S. Replication protein A promotes 5′→ 3′ end processing during homology-dependent DNA double-strand break repair. J. Cell Biol. 192(2), 251–261 (2011).
  Medline CASGoogle Scholar
• 78 Hass CS, Lam K, Wold MS. Repair-specific functions of replication protein A. J. Biol. Chem. 287(6), 3908–3918 (2012).• Clearly written manuscript detailing a critical protein in nucleotide excision repair that could be a valuable target for cancer therapeutics.
  Medline CASGoogle Scholar
• 79 Frank AO, Feldkamp MD, Kennedy JP et al. Discovery of a potent inhibitor of replication protein a protein–protein interactions using a fragment-linking approach. J. Med. Chem. 56(22), 9242–9250 (2013).
  Medline CASGoogle Scholar
• 80 Renodon-Cornire A, Weigel P, Le M, Fleury F. New potential therapeutic approaches by targeting Rad51-dependent homologous recombination. In: New Research Directions in DNA Repair. Chen C (Ed.). InTech, AZ, USA, 467–488 (2013).• Strong review of a target for homologous recombination (HR) and the potential for therapeutic indications.
  Google Scholar
• 81 Chen G, Yuan S-SF, Liu W et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 274(18), 12748–12752 (1999).
  Medline CASGoogle Scholar
• 82 Budke B, Logan HL, Kalin JH et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 40(15), 7347–7357 (2012).
  Medline CASGoogle Scholar
• 83 Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Bophys. Acta 1823(3), 742–755 (2012).
  Medline CASGoogle Scholar
• 84 Dinitto JP, Wu JC. Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. Crt. Rev. Biochem. Mol. Biol. 46(4), 295–309 (2011).
  Medline CASGoogle Scholar
• 85 Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Ann. Rev. Biochem. 80, 769–795 (2011).
  Medline CASGoogle Scholar
• 86 Roberts RJ, Agius C, Saliba C, Bossier P, Sung YY. Heat shock proteins (chaperones) in fish and shellfish and their potential role in relation to fish health: a review. J. Fish Dis. 33(10), 789–801 (2010).
  Medline CASGoogle Scholar
• 87 Mittelman D, Sykoudis K, Hersh M, Lin Y, Wilson JH. Hsp90 modulates CAG repeat instability in human cells. Cell Stress Chaperones 15(5), 753–759 (2010).
  Medline CASGoogle Scholar
• 88 Messaoudi A, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med. Chem. 8, 761–782 (2008).
  Medline CASGoogle Scholar
• 89 Meek K, Dang V, Lees-Miller SP. Chapter 2 DNA-PK. 99, 33–58 (2008).
  Google Scholar
• 90 Collis SJ, Deweese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 24(6), 949–961 (2005).
  Medline CASGoogle Scholar
• 91 Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res. 18(1), 114–124 (2008).
  Medline CASGoogle Scholar
• 92 Weinfeld M, Lees-Miller SP. DNA double-strand break repair by nonhomologous end joining and its clinical relevance. In: DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications. Kelley MR (Ed.). Academic Press, MA, USA, 161–181 (2012).
  Google Scholar
• 93 Davidson D, Amrein L, Panasci L, Aloyz R. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front. Pharmacol. 4, 5 (2013).•• Outstanding review of aspects of DNA repair pathways and upstream signaling targets that could be strong targets for anti-DNA repair therapy.
  MedlineGoogle Scholar
• 94 Zhou X, Zhang X, Xie Y, Tanaka K, Wang B, Zhang H. DNA-PKcs inhibition sensitizes cancer cells to carbon-ion irradiation via telomere capping disruption. PLoS ONE 8(8), e72641 (2013).
  Medline CASGoogle Scholar
• 95 Srivastava M, Nambiar M, Sharma S et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151(7), 1474–1487 (2012).
  Medline CASGoogle Scholar
• 96 Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother. Pharmacol. 69(1), 155–164 (2012).
  Medline CASGoogle Scholar
• 97 Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14(1), 34–43 (2012).
  Medline CASGoogle Scholar
• 98 Freschauf GK, Karimi-Busheri F, Ulaczyk-Lesanko A et al. Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase. Cancer Res. 69(19), 7739–7746 (2009).
  Medline CASGoogle Scholar
• 99 Chen X, Zhong S, Zhu X et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 68(9), 3169–3177 (2008).
  Medline CASGoogle Scholar
• 100 Park SB, Goldstein D, Krishnan AV et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin. 63(6), 419–437 (2013).
  MedlineGoogle Scholar
• 101 Fallon MT. Neuropathic pain in cancer. Br. J. Anaesth. 111(1), 105–111 (2013).
  Medline CASGoogle Scholar
• 102 Alberti P, Rossi E, Cornblath DR et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann. Oncol. 25(1), 257–264 (2013).
  MedlineGoogle Scholar
• 103 Duarte DB, Vasko MR. The role of DNA damage and repair in neurotoxicity caused by cancer therapies. In: DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications. Kelley MR (Ed.). Academic Press, MA, USA, 283–299 (2012).
  Google Scholar
• 104 Schroder S, Beckmann K, Franconi G et al. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evid. Based Complement. Alternat. Med. 2013, 423713 (2013).
  MedlineGoogle Scholar
• 105 Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin. Nutr. 32(6), 888–893 (2013).
  Medline CASGoogle Scholar
• 106 Vasko MR, Guo C, Thompson EL, Kelley MR. The repair function of the multifunctional DNA repair/redox protein APE1 is neuroprotective after ionizing radiation. DNA Repair 10(9), 942–952 (2011).
  Medline CASGoogle Scholar
• 107 Englander EW. DNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesions. DNA Repair 12(8), 685–690 (2013).
  Medline CASGoogle Scholar
• 108 Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: so if they don’t divide what’s to repair? Mutat. Res. 614(1–2), 24–36 (2007).
  Medline CASGoogle Scholar
• 109 Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. 28(3–4), 375–395 (2007).
  Medline CASGoogle Scholar
• 110 Palanca A, Casafont I, Berciano MT, Lafarga M. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell. Mol. Life Sci. (71, 1961–1975 (2013).
  MedlineGoogle Scholar
• 111 Azevedo MI, Pereira AF, Nogueira RB et al. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy. Mol. Pain 9(1), 53 (2013).
  MedlineGoogle Scholar
• 112 Dzagnidze A, Katsarava Z, Makhalova J et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 27(35), 9451–9457 (2007).
  Medline CASGoogle Scholar
• 113 Jiang Y, Guo C, Vasko MR, Kelley MR. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 68(15), 6425–6434 (2008).•• Another article in a string of publications implicating BER in chemotherapy-induced peripheral neuropathy and importance in understanding mechanisms of CIPN for future drug development.
  Medline CASGoogle Scholar
• 114 Ta LE, Schmelzer JD, Bieber AJ et al. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS ONE 8(1), e54161 (2013).
  Medline CASGoogle Scholar
• 115 Peddi SR, Chattopadhyay R, Naidu CV, Izumi T. The human apurinic/apyrimidinic endonuclease-1 suppresses activation of poly(adp-ribose) polymerase-1 induced by DNA single strand breaks. Toxicology 224(1–2), 44–55 (2006).
  Medline CASGoogle Scholar
• 116 Kono T, Hata T, Morita S et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother. Pharmacol. 72(6), 1283–1290 (2013).
  Medline CASGoogle Scholar
• 117 Gilchrist LS, Marais L, Tanner L. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support. Care Cancer 22(2), 359–366 (2013).
  MedlineGoogle Scholar
• 118 Di Francia R, Siesto RS, Valente D et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anticancer Drugs 24(10), 1069–1078 (2013).
  Medline CASGoogle Scholar
• 119 Genentech & Inotek Enter into Exclusive Global Strategic Alliance for the Discovery, Development and Commercialization of PARP Inhibitors for Cancer (2006). www.gene.com/media/press-releases/9907/2006-07-25/genentech-inotek-enter-into-exclusive-gl 
  Google Scholar
• 120 Tracon Pharma Programs (2013). www.traconpharma.com/progrms.php
  Google Scholar
• 121 Sentinel Oncology R&D Programmes (2013). www.sentineloncology.com/pipeline
  Google Scholar
• 122 Allison M. Haseltine’s DNA repair company steps out (2007). www.xconomy.com/boston/2007/12/07/haseltines-dna-repair-company-steps-out/ 
  Google Scholar
• 123 Garber K. Mission therapeutics. Nat. Biotechnol. 30(3), 206 (2012).
  Medline CASGoogle Scholar
• 124 Ubiquitination: labelling the proteins (2008). www.sebiology.org/publications/Bulletin/March08/Ubiquitination.html?
  Google Scholar
• 125 US FDA. Paving the Way for Personalized Medicine. FDA’s Role in a new Era of Medical Product Development. US Department of Health and Human Services, DC, USA, 1–61 (2013).
  Google Scholar
• 126 Perry C, Sultana R, Madhusudan S. Personalized cancer medicine: DNA repair alterations are promising predictive biomarkers in cancer. In: DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications. Kelley MR (Ed.). Academic Press, MA, USA, 257–275 (2012).
  Google Scholar
• 127 About Foundation Medicine (2013). www.foundationmedicine.com/about.php
  Google Scholar
• 128 Ho AY, Atencio DP, Peters S et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int. J. Radiat. Oncol. Biol. Phys. 65(3), 646–655 (2006).
  MedlineGoogle Scholar
• 129 Milanowska K, Krwawicz J, Papaj G et al. REPAIRtoire – a database of DNA repair pathways. Nucleic Acids Res. 39(Database issue), D788–D792 (2011).
  Medline CASGoogle Scholar
• 130 Morgenroth A, Vogg AT, Zlatopolskiy BD, Siluschek M, Oedekoven C, Mottaghy FM. Breaking the invulnerability of cancer stem cells: two-step strategy to kill the stem-like cell subpopulation of multiple myeloma. Mol. Cancer Ther. 13(1), 144–153 (2013).
  MedlineGoogle Scholar
• 131 Rowe BP, Glazer PM. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res. 12(203), 1–11 (2010).
  Google Scholar
• 132 Aziz K, Nowsheen S, Georgakilas AG. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. Curr. Mol. Med. 10(7), 626–639 (2010).
  Medline CASGoogle Scholar